8 Feb 2024 • PDE5I initiation in men with ED was associated with a lower risk of AD, particularly in those most frequently issued prescriptions, as per new research findngs.

• Analyzing data from nearly 269,725 men aged 40 and above, researchers found that the initiation of phosphodiesterase type 5 inhibitors (PDE5Is) was associated with a lower risk of Alzheimer's disease (AD) compared to nonuse, with an adjusted hazard ratio (HR) of 0.82.
• Notably, the risk decreased further with more frequent PDE5I prescriptions, with HRs of 0.56 for 21–50 prescriptions and 0.65 for >50 prescriptions.

Source: Neurology | Read full story